Peptides Similar to AOD-9604
Compare AOD-9604 with related peptides and alternatives
📌TL;DR
- •6 similar peptides identified
- •Tesamorelin: Moderate - Both target fat metabolism through GH-related pathways
- •Semaglutide: Low-Moderate - Both studied for weight management, different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| AOD-9604 (current) | - | - |
| Tesamorelin | Moderate - Both target fat metabolism through GH-related pathways | Tesamorelin is an FDA-approved GHRH analog that stimulates endogenous GH release, affecting the full spectrum of GH actions. AOD-9604 is an hGH fragment that acts independently of the GH receptor. |
| Semaglutide | Low-Moderate - Both studied for weight management, different mechanisms | Semaglutide is a GLP-1 receptor agonist with robust clinical evidence for weight loss (15-20% body weight). AOD-9604 targets lipolysis via beta-3 AR upregulation and failed to show significant weight loss in clinical trials. |
| CJC-1295 with DAC | Moderate - Both related to GH axis but through different mechanisms | CJC-1295 DAC is a long-acting GHRH analog that stimulates pituitary GH release and elevates IGF-1. AOD-9604 is an hGH fragment with no GH receptor interaction or IGF-1 effects. |
| CJC-1295 without DAC | Moderate - Both short-acting peptides in the GH/metabolic space | CJC-1295 without DAC stimulates pulsatile GH release through GHRH receptor activation. AOD-9604 does not stimulate GH release or act through the GH receptor. |
| Ipamorelin | Low-Moderate - Both used in metabolic research, entirely different mechanisms | Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release from the pituitary. AOD-9604 does not interact with the ghrelin receptor or stimulate GH release. |
| Tirzepatide | Low - Both in metabolic/weight management space, vastly different evidence levels | Tirzepatide is a dual GIP/GLP-1 receptor agonist with the strongest clinical weight loss data of any pharmaceutical agent (up to 22.5% body weight loss). AOD-9604 failed its weight loss trial. |
TesamorelinModerate - Both target fat metabolism through GH-related pathways
Differences
Tesamorelin is an FDA-approved GHRH analog that stimulates endogenous GH release, affecting the full spectrum of GH actions. AOD-9604 is an hGH fragment that acts independently of the GH receptor.
Advantages
FDA-approved for HIV-associated lipodystrophy; proven efficacy for visceral fat reduction in clinical trials
Disadvantages
Elevates IGF-1 levels; full GH axis stimulation with broader systemic effects
SemaglutideLow-Moderate - Both studied for weight management, different mechanisms
Differences
Semaglutide is a GLP-1 receptor agonist with robust clinical evidence for weight loss (15-20% body weight). AOD-9604 targets lipolysis via beta-3 AR upregulation and failed to show significant weight loss in clinical trials.
Advantages
FDA-approved for obesity (Wegovy); vastly stronger clinical evidence; 15-20% weight loss in trials
Disadvantages
Different mechanism; significant GI side effects (nausea, vomiting); expensive
CJC-1295 with DACModerate - Both related to GH axis but through different mechanisms
Differences
CJC-1295 DAC is a long-acting GHRH analog that stimulates pituitary GH release and elevates IGF-1. AOD-9604 is an hGH fragment with no GH receptor interaction or IGF-1 effects.
Advantages
Sustained GH elevation; broader anabolic effects; longer half-life
Disadvantages
Elevates IGF-1; affects glucose metabolism; not GH-receptor-independent
CJC-1295 without DACModerate - Both short-acting peptides in the GH/metabolic space
Differences
CJC-1295 without DAC stimulates pulsatile GH release through GHRH receptor activation. AOD-9604 does not stimulate GH release or act through the GH receptor.
Advantages
Mimics natural pulsatile GH release; established synergy with GHRP peptides
Disadvantages
Requires multiple daily injections; elevates IGF-1; broader hormonal effects
IpamorelinLow-Moderate - Both used in metabolic research, entirely different mechanisms
Differences
Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release from the pituitary. AOD-9604 does not interact with the ghrelin receptor or stimulate GH release.
Advantages
Highly selective GH stimulation with minimal cortisol or prolactin elevation
Disadvantages
Stimulates GH axis broadly; not specific to fat metabolism
TirzepatideLow - Both in metabolic/weight management space, vastly different evidence levels
Differences
Tirzepatide is a dual GIP/GLP-1 receptor agonist with the strongest clinical weight loss data of any pharmaceutical agent (up to 22.5% body weight loss). AOD-9604 failed its weight loss trial.
Advantages
FDA-approved; up to 22.5% weight loss in trials; dual receptor mechanism
Disadvantages
Different mechanism; significant GI side effects; requires prescription
Overview#
AOD-9604 occupies a unique position in the landscape of metabolic and weight-management peptides. As an hGH C-terminal fragment, it was designed to isolate the lipolytic properties of growth hormone from its growth-promoting effects. However, its clinical development for obesity was terminated after Phase IIb failure, placing it in a different evidence category from FDA-approved agents like semaglutide or tesamorelin.
When comparing AOD-9604 with similar peptides, the most important distinction is between peptides with proven clinical efficacy and regulatory approval versus those that remain investigational. AOD-9604 falls into the latter category for all indications, including both obesity and cartilage repair.
Comparison by Mechanism#
GH-Related Peptides#
AOD-9604 differs fundamentally from other GH-related peptides because it does not stimulate growth hormone release or interact with the growth hormone receptor:
| Feature | AOD-9604 | Tesamorelin | CJC-1295 DAC | CJC-1295 no DAC | Ipamorelin |
|---|---|---|---|---|---|
| Mechanism | Beta-3 AR upregulation | GHRH receptor agonist | GHRH receptor agonist | GHRH receptor agonist | Ghrelin receptor agonist |
| GH release | No | Yes | Yes | Yes | Yes |
| IGF-1 elevation | No | Yes | Yes | Yes | Yes |
| FDA approved | No | Yes (lipodystrophy) | No | No | No |
| Clinical trial weight loss | Failed Phase IIb | Proven for visceral fat | No obesity trials | No obesity trials | No obesity trials |
| Glucose effects | None observed | May worsen | May worsen | May worsen | Minimal |
The key advantage claimed for AOD-9604 is its metabolic selectivity: it is reported to promote fat metabolism without the IGF-1 elevation, glucose impairment, or growth-promoting effects of GH-axis peptides. However, this advantage is offset by the clinical failure to demonstrate meaningful weight loss in humans.
Weight Loss Peptides (GLP-1 Class)#
The GLP-1 receptor agonist class represents the current standard of care for pharmacological weight management and dramatically outperforms AOD-9604 in clinical evidence:
| Feature | AOD-9604 | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Liraglutide (Saxenda) |
|---|---|---|---|---|
| Mechanism | Beta-3 AR upregulation | GLP-1 receptor agonist | GIP/GLP-1 dual agonist | GLP-1 receptor agonist |
| Weight loss | Failed Phase IIb | ~15% body weight | Up to 22.5% body weight | ~8% body weight |
| FDA approved | No | Yes | Yes | Yes |
| Route | SC injection or oral | SC injection (weekly) | SC injection (weekly) | SC injection (daily) |
| GI side effects | Minimal | Significant (nausea, vomiting) | Significant | Significant |
| Cardiovascular benefit | Unknown | Demonstrated (SELECT trial) | Under investigation | Not demonstrated |
For weight management specifically, the evidence overwhelmingly favors GLP-1 receptor agonists over AOD-9604. The GLP-1 class has demonstrated robust, reproducible weight loss in large Phase 3 trials, while AOD-9604 failed its pivotal trial.
Comparison by Application#
Fat Metabolism Research#
For researchers studying fat metabolism mechanisms, AOD-9604 offers a unique tool as a GH fragment that promotes lipolysis through beta-3 AR upregulation without GH receptor activation. This specificity makes it useful for studying the isolated contribution of the hGH C-terminal domain to fat metabolism, independent of the broader GH signaling cascade.
In this research context, AOD-9604 has no direct equivalent, as it is the most extensively studied isolated lipolytic fragment of growth hormone.
Cartilage Repair Research#
AOD-9604 has been investigated for cartilage repair based on a single published rabbit study. In this application, the most relevant comparisons are with established cartilage-active peptides and treatments:
- Hyaluronic acid: Well-established viscosupplementation with extensive clinical data. AOD-9604 showed synergistic effects with HA in the rabbit model (PMID: 26275694).
- BPC-157: Another peptide studied for tissue repair, with a broader but primarily preclinical evidence base.
- Pentosan polysulfate: An established cartilage-active agent with clinical data in osteoarthritis.
For cartilage repair, AOD-9604 has weaker evidence than established therapies and should not be considered as a clinically validated alternative.
Growth Hormone Fragment Comparison#
AOD-9604 is sometimes compared with the closely related hGH Fragment 176-191 (the unmodified C-terminal fragment without the tyrosine substitution). The key differences are:
- AOD-9604 has the tyrosine substitution at the N-terminus (replacing the native phenylalanine) for improved stability
- AOD-9604 has a clinical development history with published human safety data
- hGH Fragment 176-191 has minimal independent published research
- The two peptides are sometimes conflated in non-scientific literature, but they are distinct compounds with different amino acid sequences
Summary#
AOD-9604's position among similar peptides is defined by two contrasting features: an extensive human safety database that exceeds most research peptides, and a clinical efficacy failure that places it below approved therapeutics. For researchers studying GH fragment biology and lipolytic mechanisms, AOD-9604 remains a valuable pharmacological tool. For individuals seeking weight management solutions, FDA-approved GLP-1 receptor agonists have vastly stronger evidence of efficacy.
Related Reading#
Frequently Asked Questions About AOD-9604
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer